Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Melatonin (meta)
Aspirin (meta) Metformin (meta)
Bamlaniv../e.. (meta) Molnupiravir (meta)
Bebtelovimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Cannabidiol (meta) Nitric Oxide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Lactoferrin (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Progression 51% Improvement Relative Risk Viral clearance, day 7 -50% Viral clearance, PP, day7 -56% Time to viral- -17% c19hcq.com Nimitvilai et al. NCT02045069 HCQ RCT EARLY TREATMENT Favors HCQ Favors ivermectin a..
Nimitvilai, 113 patient HCQ early treatment RCT: 50% worse viral clearance [p=0.12] https://c19p.org/nimitvilaih
copied to clipboard
A randomized controlled trial of combined ivermectin and zinc sulfate versus combined hydroxychloroquine, darunavir/ritonavir, and zinc sulfate among adult patients with asymptomatic or mild coronavirus-19 infection
Nimitvilai et al., Journal of Global Infectious Diseases, doi:10.4103/jgid.jgid_281_21, NCT02045069 (history)
29 Jun 2022    Source   PDF   Share   Tweet
RCT low-risk patients in Thailand comparing HCQ, darunavir/ritonavir, and zinc, with ivermectin and zinc, showing no significant differences. All patients recovered. 65% of patients were asymptomatic at baseline, 26% were PCR- at baseline, and 84% were culture negative at baseline. The percentage of patients symptomatic at baseline was 15% higher for ivermectin.
The reported trial id NCT02045069 (history) is a 2014 dengue trial with a status of recruiting [clinicaltrials.gov]. Authors claim both treatments had no clinical benefit, however all patients were discharged from quarantine as planned between 10-14 days, and there was no control group. Authors claim there was "no clear evidence of antiviral effects for the control arm", however there was no control arm. Authors indicate that all patients were discharged within 14 days, however they report that one patient had Ct 22.11 at day 12.
risk of progression, 50.9% lower, RR 0.49, p = 0.62, treatment 1 of 57 (1.8%), control 2 of 56 (3.6%), NNT 55.
risk of no viral clearance, 49.7% higher, RR 1.50, p = 0.12, treatment 25 of 56 (44.6%), control 17 of 57 (29.8%), mid-recovery, day 7, modified intention-to-treat.
risk of no viral clearance, 56.0% higher, RR 1.56, p = 0.048, treatment 24 of 38 (63.2%), control 17 of 42 (40.5%), mid-recovery, day 7, per-protocol.
time to viral-, 16.7% higher, relative time 1.17, p = 0.42, treatment 57, control 56.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Nimitvilai et al., 6/29/2022, Randomized Controlled Trial, Thailand, peer-reviewed, 10 authors, study period December 2020 - April 2021, this trial compares with another treatment - results may be better when compared to placebo, this trial uses multiple treatments in the treatment arm (combined with darunavir/ritonavir and zinc sulfate) - results of individual treatments may vary, trial NCT02045069 (history).
Contact: ysuputtamongkol@gmail.com.
All Studies   Meta Analysis
This PaperHCQAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit